-
Something wrong with this record ?
Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein
J. Hurnakova, H. Hulejova, J. Zavada, M. Komarc, LA. Cerezo, H. Mann, J. Vencovsky, K. Pavelka, L. Senolt,
Language English Country Germany
Document type Journal Article
NLK
ProQuest Central
from 1997-01-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2000-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 1997-01-01 to 1 year ago
- MeSH
- Biomarkers blood MeSH
- C-Reactive Protein analysis MeSH
- Blood Sedimentation MeSH
- Leukocyte L1 Antigen Complex blood MeSH
- Middle Aged MeSH
- Humans MeSH
- Reference Values MeSH
- Arthritis, Rheumatoid blood MeSH
- Severity of Illness Index MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Finland MeSH
Approximately half of patients with rheumatoid arthritis (RA) have normal C-reactive protein (CRP) levels. Calprotectin is a promising and likely more specific biomarker of disease activity than conventionally used acute phase reactants. We aimed to analyse the levels of serum calprotectin in RA patients with clinically active disease and with normal/low CRP. A total of 160 RA patients underwent clinical examination (DAS28-ESR and CDAI). The levels of calprotectin were analysed in patients with moderate to high disease activity with normal/low CRP levels and in 32 healthy subjects. The discriminatory capacity of calprotectin to identify clinically active patients in spite of normal/low CRP was assessed using ROC curves. Out of all RA patients, 74/160 (46.3%) were in remission or had low disease activity according to DAS28 and had normal/low CRP levels. However, 51/160 (32%) had normal/low CRP levels despite having moderate to high disease activity. In these patients, calprotectin levels were significantly higher than those in patients who had normal/low CRP and were in remission or showed low disease activity (2.7 ± 1.5 vs. 2.1 ± 1.2 μg/mL, p = 0.043), which differed from those in healthy subjects (2.7 ± 1.5 vs. 1.9 ± 1.2 μg/mL, p = 0.011). The discriminatory capacity for calprotectin to distinguish clinically active vs. inactive disease despite normal/low CRP using AUC of the DAS28 was 0.607 (95% CI 0.503 to 0.711, p = 0.043). The present study demonstrates that calprotectin may reflect inflammatory activity in RA patients where CRP fails to do so.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19012722
- 003
- CZ-PrNML
- 005
- 20220111131706.0
- 007
- ta
- 008
- 190405s2018 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s10067-018-4091-5 $2 doi
- 035 __
- $a (PubMed)29656372
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Hurňáková, Jana $u Institute of Rheumatology, Prague, Czech Republic, Na Slupi 4, 120 50, Prague 2, Czech Republic. Department of Rheumatology, First Faculty of Medicine, Charles University in Prague, Czech Republic, Na Slupi 4, 120 50, Prague 2, Czech Republic. $7 xx0268288
- 245 10
- $a Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein / $c J. Hurnakova, H. Hulejova, J. Zavada, M. Komarc, LA. Cerezo, H. Mann, J. Vencovsky, K. Pavelka, L. Senolt,
- 520 9_
- $a Approximately half of patients with rheumatoid arthritis (RA) have normal C-reactive protein (CRP) levels. Calprotectin is a promising and likely more specific biomarker of disease activity than conventionally used acute phase reactants. We aimed to analyse the levels of serum calprotectin in RA patients with clinically active disease and with normal/low CRP. A total of 160 RA patients underwent clinical examination (DAS28-ESR and CDAI). The levels of calprotectin were analysed in patients with moderate to high disease activity with normal/low CRP levels and in 32 healthy subjects. The discriminatory capacity of calprotectin to identify clinically active patients in spite of normal/low CRP was assessed using ROC curves. Out of all RA patients, 74/160 (46.3%) were in remission or had low disease activity according to DAS28 and had normal/low CRP levels. However, 51/160 (32%) had normal/low CRP levels despite having moderate to high disease activity. In these patients, calprotectin levels were significantly higher than those in patients who had normal/low CRP and were in remission or showed low disease activity (2.7 ± 1.5 vs. 2.1 ± 1.2 μg/mL, p = 0.043), which differed from those in healthy subjects (2.7 ± 1.5 vs. 1.9 ± 1.2 μg/mL, p = 0.011). The discriminatory capacity for calprotectin to distinguish clinically active vs. inactive disease despite normal/low CRP using AUC of the DAS28 was 0.607 (95% CI 0.503 to 0.711, p = 0.043). The present study demonstrates that calprotectin may reflect inflammatory activity in RA patients where CRP fails to do so.
- 650 _2
- $a revmatoidní artritida $x krev $7 D001172
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 _2
- $a krevní sedimentace $7 D001799
- 650 _2
- $a C-reaktivní protein $x analýza $7 D002097
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a leukocytární L1-antigenní komplex $x krev $7 D039841
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a referenční hodnoty $7 D012016
- 650 _2
- $a stupeň závažnosti nemoci $7 D012720
- 651 _2
- $a Finsko $7 D005387
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Hulejova, Hana $u Institute of Rheumatology, Prague, Czech Republic, Na Slupi 4, 120 50, Prague 2, Czech Republic.
- 700 1_
- $a Zavada, Jakub $u Institute of Rheumatology, Prague, Czech Republic, Na Slupi 4, 120 50, Prague 2, Czech Republic. Department of Rheumatology, First Faculty of Medicine, Charles University in Prague, Czech Republic, Na Slupi 4, 120 50, Prague 2, Czech Republic.
- 700 1_
- $a Komarc, Martin $u Department of Methodology, Faculty of Physical Education and Sport, Charles University in Prague, Czech Republic, José Martího 31, 162 52, Prague 6, Czech Republic.
- 700 1_
- $a Cerezo, Lucie Andres $u Institute of Rheumatology, Prague, Czech Republic, Na Slupi 4, 120 50, Prague 2, Czech Republic.
- 700 1_
- $a Mann, Herman $u Institute of Rheumatology, Prague, Czech Republic, Na Slupi 4, 120 50, Prague 2, Czech Republic. Department of Rheumatology, First Faculty of Medicine, Charles University in Prague, Czech Republic, Na Slupi 4, 120 50, Prague 2, Czech Republic.
- 700 1_
- $a Vencovsky, Jiri $u Institute of Rheumatology, Prague, Czech Republic, Na Slupi 4, 120 50, Prague 2, Czech Republic. Department of Rheumatology, First Faculty of Medicine, Charles University in Prague, Czech Republic, Na Slupi 4, 120 50, Prague 2, Czech Republic.
- 700 1_
- $a Pavelka, Karel $u Institute of Rheumatology, Prague, Czech Republic, Na Slupi 4, 120 50, Prague 2, Czech Republic. Department of Rheumatology, First Faculty of Medicine, Charles University in Prague, Czech Republic, Na Slupi 4, 120 50, Prague 2, Czech Republic.
- 700 1_
- $a Senolt, Ladislav $u Institute of Rheumatology, Prague, Czech Republic, Na Slupi 4, 120 50, Prague 2, Czech Republic. senolt@revma.cz. Department of Rheumatology, First Faculty of Medicine, Charles University in Prague, Czech Republic, Na Slupi 4, 120 50, Prague 2, Czech Republic. senolt@revma.cz.
- 773 0_
- $w MED00001162 $t Clinical rheumatology $x 1434-9949 $g Roč. 37, č. 8 (2018), s. 2055-2062
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29656372 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190405 $b ABA008
- 991 __
- $a 20220111131701 $b ABA008
- 999 __
- $a ok $b bmc $g 1392032 $s 1051027
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 37 $c 8 $d 2055-2062 $e 20180414 $i 1434-9949 $m Clinical rheumatology $n Clin Rheumatol $x MED00001162
- LZP __
- $a Pubmed-20190405